证券代码：600976 证券简称：健民集团 公告编号：2025-032 健民药业集团股份有限公司 第十一届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 详 见 中 国 证 券 报 、 证 券 时 报 、 上 海 证 券 报 及 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）公司披露的《健民药业集团股份有限公司 2025 年半年度报告》 及其摘要。 2、关于修订公司治理相关制度的议案 同意：9 票 弃权：0 票 反对：0 票 根据公司 2025 年第一次临时股东大会批准的《公司章程》，修订内部控制制度、 对外部单位报送信息管理制度、高级管理人员薪酬与考核管理办法、董事会审计委 员会年报工作规程、独立董事年报工作制度等上市公司治理相关的 5 项制度，其中 《高级管理人员薪酬与考核管理办法》经第十一届董事会薪酬与考核委员会第二次 会议审议通过，详见中国证券报、证券时报、上海证券报及上海证券交易所网站 （www.sse.com.cn）公司披露的《健民药业集团股份有限公司制度文件（ ...

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 1,804,599,192.51, a decrease of 10.20% compared to CNY 2,009,596,097.48 in the same period last year[20]. - The total profit for the reporting period was CNY 239,227,613.89, down 8.21% from CNY 260,611,034.43 year-on-year[20]. - The net profit attributable to shareholders was CNY 220,625,625.18, reflecting a decline of 7.83% from CNY 239,357,528.02 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 195,481,795.67, a slight increase of 0.61% compared to CNY 194,297,661.98 last year[20]. - The net cash flow from operating activities was CNY 55,695,141.55, showing a marginal increase of 0.84% from CNY 55,231,620.77 in the same period last year[20]. - The basic earnings per share decreased to CNY 1.46, down 6.41% from CNY 1.56 in the same period last year[21]. - The weighted average return on net assets decreased by 2.44 percentage points to 8.83% from 11.27% year-on-year[21]. - The company achieved a revenue of 18.05 billion yuan in the first half of 2025, a year-on-year decrease of 10.20%, with a net profit of 2.21 billion yuan, down 7.83% year-on-year[32]. - The company reported a total of 978,684.68 RMB in overseas assets, accounting for 0.02% of total assets[71]. Revenue Breakdown - The decline in operating revenue was primarily due to a 37.82% decrease in pharmaceutical commercial revenue, while pharmaceutical industrial revenue grew by 23.07%[22]. - The decline in revenue was primarily due to a 37.82% drop in the pharmaceutical commercial sector, while the pharmaceutical manufacturing sector saw growth[32]. - The pharmaceutical manufacturing industry reported a revenue of 12,275.2 billion yuan in the first half of 2025, a year-on-year decrease of 1.20%[35]. Investment and R&D - Research and development expenses increased by 30.89% to approximately ¥52.97 million, reflecting the company's commitment to enhancing its R&D capabilities[67]. - The company is focusing on R&D innovation as a core driver for development, with increased investment in automation, digitalization, and green low-carbon initiatives[50]. - The company plans to accelerate the commercialization of new prescription products, including innovative drugs like the Seven-Rui Wei-Shu capsule and pediatric products[56]. - The company has launched three new traditional Chinese medicine projects and accelerated the development of existing products, enhancing its product pipeline[58]. Market Position and Strategy - The company focuses on OTC and prescription drug lines, with key products like Longmu Zhuanggu Granules and Bian Tong Capsules leading the market[28]. - The OTC product line has been ranked first in pediatric digestive products for four consecutive years[28]. - The company operates a pharmaceutical wholesale and retail business primarily in Guangdong and Hubei provinces[29]. - The company’s OTC products are sold through online and offline pharmacy channels, while Rx products are promoted through specialized academic channels[31]. - The company is focusing on expanding its sales resources to community hospitals and rural health clinics, aligning with government efforts to improve grassroots healthcare infrastructure[47]. Compliance and Governance - The company is committed to compliance and has established a compliance committee to prevent commercial bribery, enhancing the integrity of its sales processes[41]. - The company emphasizes continuous improvement in governance, competitiveness, innovation, risk resistance, and return capabilities to align management capabilities with development stages and scales[81]. - The company maintains a good integrity status, with no significant debts or court judgments unmet during the reporting period[89]. Financial Position - Total assets increased by 1.12% to CNY 4,325,472,492.96 from CNY 4,277,629,406.13 at the end of the last year[20]. - The net assets attributable to shareholders at the end of the reporting period were CNY 2,517,872,472.06, up 3.39% from CNY 2,435,305,586.88 at the end of the previous year[20]. - The company's total equity reached CNY 2,161,718,317.67 in the first half of 2025, slightly up from CNY 2,159,487,891.05 in the first half of 2024[113]. Risks and Challenges - The company faces risks from industry policy changes, intensified market competition, and fluctuations in raw material prices, which could impact profitability[79][80]. - The ongoing centralized procurement of traditional Chinese medicine is expected to pose pricing risks for future pharmaceutical sales[48]. - The company has experienced risks related to talent loss due to the technical-intensive nature of the pharmaceutical industry, prompting the implementation of a robust talent cultivation program[81]. Shareholder Information - The company has a total of 17,012 common shareholders as of the end of the reporting period[99]. - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 24.13% of the shares, totaling 37,014,073 shares[101]. - The company has not reported any changes in major shareholders or strategic investors during the reporting period[104]. Environmental and Social Responsibility - The company aims for zero accidents in safety and environmental protection, enhancing its safety training and emergency drills[59]. - The company has established four traditional Chinese medicine clinics in Wuhan, expanding its healthcare services[30]. Financial Reporting and Accounting - The financial report was approved by the board on August 19, 2025, reflecting the company's financial status as of June 30, 2025[146]. - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[148][149]. - The company follows a 12-month operating cycle for liquidity classification of assets and liabilities[153].

北京商报讯（记者 丁宁）8月19日晚间，健民集团（600976）披露2025年半年报显示，公司上半年实现 的营业收入为18.05亿元，同比下降10.2%；归属净利润为2.21亿元，同比下降7.83%。 健民集团表示，本期营业收入同比下降10.2%，其中医药工业收入增长23.07%，医药商业收入下降 37.82%。医药商业收入下降主要是公司持续优化下属商业子公司业务结构，逐步收缩了部分低毛低效 的业务，导致医药商业板块业务收入有所下降，但公司医药商业板块加大创新性业务如医院SPD业务等 的拓展，业务结构得到持续优化。医药商业板块对公司利润贡献有限，收入的下降对利润的影响不大。 ...

Core Points - The company reported a decline in both operating revenue and net profit for the first half of 2025, with operating revenue at 1.805 billion yuan, a year-on-year decrease of 10.2%, and net profit at 221 million yuan, down 7.83% year-on-year [2] Summary by Category - **Financial Performance** - Operating revenue decreased to 1.805 billion yuan, representing a 10.2% decline compared to the previous year [2] - Net profit fell to 221 million yuan, reflecting a year-on-year decrease of 7.83% [2] - **Reasons for Decline** - The primary reasons for the decline in financial performance were reduced investment income from joint ventures and a decrease in non-recurring gains and losses [2]

Core Insights - The company reported a revenue of 1.805 billion yuan for the first half of 2025, representing a year-on-year decrease of 10.20% [1] - The net profit attributable to shareholders was 221 million yuan, down 7.83% year-on-year [1] - The net profit excluding non-recurring gains and losses was 195 million yuan, showing a year-on-year increase of 0.61% [1] - The basic earnings per share stood at 1.46 yuan [1]

Core Insights - The company reported a revenue of 1.805 billion yuan for the first half of 2025, representing a year-on-year decline of 10.20% [1] - The net profit for the same period was 221 million yuan, showing a year-on-year decrease of 7.83% [1] Financial Performance - Revenue: 1.805 billion yuan, down 10.20% year-on-year [1] - Net Profit: 221 million yuan, down 7.83% year-on-year [1]

Group 1 - The company has received the clinical trial approval notice for the nasal congestion granules from the National Medical Products Administration [1] - The nasal congestion granules are indicated for the treatment of acute sinusitis and have shown good efficacy and safety in clinical applications [1][2] - The market for nasal medication is significant, with 26% of the adult population in China suffering from nasal inflammation or sinusitis, and the market demand for nasal medication is expected to grow [2] Group 2 - The sales revenue for nasal medication (traditional Chinese medicine) is projected to be 2.757 billion yuan in 2023 and 3.061 billion yuan in 2024, with the nasal congestion granules expected to generate sales of 409 million yuan in 2023 and 475 million yuan in 2024 [2] - There are several traditional Chinese medicine products approved for the treatment of acute sinusitis, including nasal congestion granules, with one approval number for the nasal congestion granules [3] - The company must complete clinical trials and submit a marketing authorization application to the National Medical Products Administration before the product can be marketed [4]

Core Viewpoint - Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating progress in its product development pipeline [2] Company Summary - Jianmin Group announced on August 14 that it has obtained the clinical trial approval from the National Medical Products Administration for its nasal medication, Nasal Congestion Relief Granules [2]

Group 1 - The core point of the article is that Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating a significant development in its product pipeline [2] - Jianmin Group's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 49.83%, pharmaceutical commerce for 49.56%, and other businesses for 0.6% [2]

证券简称：健民集团 证券代码：600976 公告编号：2025-031 健民药业集团股份有限公司 关于获得《药物临床试验批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的鼻渊通窍颗粒《药物临床试验批准通知书》。按照《上海证券交易所 上市公司自律监管指引第3号——行业信息披露》的相关要求，现将有关情况公告 如下： | 药品名称 | 鼻渊通窍颗粒 | 申请人 | 健民药业集团股份有限公司 | | --- | --- | --- | --- | | 注册分类 | 中药4类 | 剂型 | 颗粒剂 | | 通知书编号 | 2025LP02040 | 受理号 | CYZL2500001 | | 适应症 | 急性鼻窦炎 | | | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，鼻渊通窍颗粒临床试 | | | | | 验申请符合药品注册的有关要求，同意本品开展用于急性鼻窦炎的临床 | | | | | 试验。 | | | 二、药 ...